BCRX - BioCryst Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
Enterprise Value 3
Trailing P/E
Forward P/E 1
PEG Ratio (5 yr expected) 1
Price/Sales (ttm)
Price/Book (mrq)
Enterprise Value/Revenue 3
Enterprise Value/EBITDA 6

Trading Information

Stock Price History

Beta (3Y Monthly) 1.73
52-Week Change 3-66.04%
S&P500 52-Week Change 35.71%
52 Week High 39.9500
52 Week Low 32.3500
50-Day Moving Average 32.8983
200-Day Moving Average 34.4336

Share Statistics

Avg Vol (3 month) 31.43M
Avg Vol (10 day) 3984.5k
Shares Outstanding 5110.44M
Float 75.68M
% Held by Insiders 11.04%
% Held by Institutions 193.64%
Shares Short (Sep 30, 2019) 414.87M
Short Ratio (Sep 30, 2019) 48.36
Short % of Float (Sep 30, 2019) 418.21%
Short % of Shares Outstanding (Sep 30, 2019) 413.47%
Shares Short (prior month Aug 30, 2019) 414.68M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019


Profit Margin 0.00%
Operating Margin (ttm)-929.01%

Management Effectiveness

Return on Assets (ttm)-52.87%
Return on Equity (ttm)-679.69%

Income Statement

Revenue (ttm)11.52M
Revenue Per Share (ttm)0.11
Quarterly Revenue Growth (yoy)-88.40%
Gross Profit (ttm)-64.71M
EBITDA -106.25M
Net Income Avi to Common (ttm)-125.71M
Diluted EPS (ttm)-1.1540
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)92.15M
Total Cash Per Share (mrq)0.83
Total Debt (mrq)84.38M
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)1.44
Book Value Per Share (mrq)-0.08

Cash Flow Statement

Operating Cash Flow (ttm)-110.52M
Levered Free Cash Flow (ttm)-56.04M